BioCentury
ARTICLE | Company News

BIOCND Inc., Genor Biopharma deal

June 10, 2013 7:00 AM UTC

Genor granted BIOCND development rights to two mAbs. Genor granted BIOCND rights to GB232, an adalimumab biosimilar, in South, Southeast and Northeast Asia (except Greater China) and Russia. It also granted BIOCND rights to GB221, a trastuzumab biosimilar, worldwide except Greater China, Japan, the U.S. and Europe. BIOCND will be responsible for international development and registration of the two products. The partners plan to submit an international IND application at the end of the year for a Phase I trial of GB232 and in early 2014 for a Phase III trial of GB221. GB221 completed a Phase I trial in Australia. Genor declined to disclose details, while BIOCND could not be reached. ...